ISSN: 1859 - 2872
Correlation between plasma levels of sPD-1 and sPD-L1 with hepatic inflammation in chronic HBV infected patients
Main Article Content
Keywords
HBV infection, chronic hepatitis B, hepatocellular carcinoma, sPD-1, sPD-L1
Abstract
Objective: The immunosuppressive PD-1/PD-L1 (programmed cell death-1/ programmed cell death ligand-1) signaling pathway is considered to play an important role in the pathogenesis of HBV infection. We conducted a prospective cohort study to assess the relationship between circulating sPD-1 and sPD-L1 (soluble forms) levels in HBV infection and live disease outcome and progression. Subject and method: Plasma sPD-1 and sPD-L1 levels were quantified using commercial ELISA kits in a prospective cohort including asymptomatic carrier (ASY, n = 30), chronic hepatitis (CHB, n = 79), hepatocellular carcinoma (HCC, n = 47) and 73 healthy individuals as control group (HC). Result: The plasma sPD-1 and sPD-L1 levels were significantly higher in HBV infected patients or in each patient groups (ASY, CHB, HCC) compared to the controls (p<0.0001). Among HBV-infected patients, plasma sPD-1 and sPD-L1 levels were higher in the CHB followed by the HCC and ASY group. The plasma levels of sPD-1 and sPD-L1 were positively correlated with hepatic inflammation markers such as AST, ALT and GGT in HBV- infected patients. Conclusion: We could show that HBV infection can induce the expression of PD-1 and PD-L1 and significantly increased levels of plasma sPD-1 and sPD-L1 are correlated with the hepatic inflammation in chronic HBV-infected patients.
Article Details
References
1. WHO (2021) Hepatitis B epidemiology. https://wwwwhoint/news-room/fact-sheets/detail/ hepatitis-b..
2. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P et al (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204(3): 667-80. doi: 10.1084/jem.20061287. PubMed PMID: 17353365; PubMed Central PMCID: PMCPMC2137916.
3. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C et al (2006) Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 36(2): 144-150. PubMed PMID: 16682509.
4. Bertoletti A, Naoumov NV (2003) Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 39(1): 115-124. doi: 10.1016/s0168-8278(03)00126-0. PubMed PMID: 12821053.
5. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y (2015) T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 6: 1694. doi: 10.1038/cddis.2015.42. PubMed PMID: 25789969; PubMed Central PMCID: PMCPMC4385920.
6. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2(2): 116-126. doi: 10.1038/nri727. PubMed PMID: 11910893.
7. Zhu X, Soluble JL (2017) PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget 8(57): 97671-97682. doi: 10.18632/oncotarget.18311.
8. Bi C, Huang D, Jiang J, Jiang Y, Wang H, Bian C et al (2018) Changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and correlation with curative effect. Turk J Med Sci 48(2): 286-292. doi: 10.3906/sag-1708-121. PubMed PMID: 29714442.
9. Li N, Zhou Z, Li F, Sang J, Han Q, Lv Y et al (2017) Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 8(28): 46020-46033. doi: 10.18632/oncotarget.17546. PubMed PMID: 28545019; PubMed Central PMCID: PMCPMC5542245.
10. Zhou L, Li X, Huang X, Chen L, Gu L, Huang Y (2019) Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J Viral Hepat 26(7): 795-802. Epub 2018/12/24. doi: 10.1111/jvh.13055. PubMed PMID: 30578715; PubMed Central PMCID: PMCPMC6849537.
11. Wang D, Zhou D, Du Q, Liang Q, Wang Q, Fang L et al (2013) Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C. Mol Med Rep 7(4): 1197-202. Epub 2013/02/22. doi: 10.3892/mmr.2013.1326. PubMed PMID: 23426717.
12. Yu X, Pan Y, Fei Q, Lin X, Chen Z, Huang H (2021) Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis. Immun Inflamm Dis 9(1): 310-318. doi: 10.1002/iid3.394. PubMed PMID: 33417300; PubMed Central PMCID: PMCPMC7860599.
13. Bakhshiani Z, Fouladi S, Mohammadzadeh S, Eskandari N (2021) Correlation of sPD1 with Procalcitonin and C-Reactive protein levels in patients with sepsis. Cell J 23(1): 14-20. doi: 10.22074/cellj.2021.6941. PubMed PMID: 33650816; PubMed Central PMCID: PMCPMC7944127.
14. Hadley T, Gillespie S, Espinoza H, Prince J, Gronbaek H, Chandrakasan S et al (2020) Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. Autoimmunity 53(5): 253-260. Epub 2020/05/07. doi: 10.1080/08916934.2020.1755964. PubMed PMID: 32370568.
15. Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L et al (2018) Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 184: 7-14. doi: 10.1016/j.imlet.2017.02.006. PubMed PMID: 28223102; PubMed Central PMCID: PMCPMC5362328.
16. Dong Y, Sun Q, Zhang X (2017) PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 8(2): 2171-86. doi: 10.18632/ oncotarget.13895. PubMed PMID: 27974689; PubMed Central PMCID: PMCPMC5356790.
17. Chang B, Huang T, Wei H, Shen L, Zhu D, He W et al (2019) The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother 68(3): 353-363. doi: 10.1007/s00262-018-2271-4. PubMed PMID: 30506460; PubMed Central PMCID: PMCPMC6426820.
18. Wang G, Wang S, Zhang M, Li Y, Liu Q, Sun N et al (2020) EV PD-L1 is correlated with clinical features and contributes to T cell suppression in pediatric thyroid cancer. J Clin Endocrinol Metab 105(8). doi: 10.1210/clinem/dgaa309. PubMed PMID: 32459310.
19. Zhu X, Lang J (2017) Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8(57): 97671-97682. doi: 10.18632/ oncotarget.18311. PubMed PMID: 29228642; PubMed Central PMCID: PMCPMC5722594.
20. Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L et al (2011) Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 56(2): 231-238. Epub 2011/07/08. doi: 10.1016/j.cyto. 2011.06.004. PubMed PMID: 21733718.
21. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N et al (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73(1): 128-138. doi: 10.1158/0008-5472.CAN-12-2606. PubMed PMID: 23135914.
22. Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Kamimura K, Tsuchiya A et al (2017) Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C. Int J Med Sci 14(5): 403-411. doi: 10.7150/ijms.18784. PubMed PMID: 28539815; PubMed Central PMCID: PMCPMC5441031.
23. Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X et al (2020) Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther 51(11): 1180-1187. Epub 2020/05/05. doi: 10.1111/apt.15732. PubMed PMID: 32363582.
2. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P et al (2007) Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204(3): 667-80. doi: 10.1084/jem.20061287. PubMed PMID: 17353365; PubMed Central PMCID: PMCPMC2137916.
3. Falasca K, Ucciferri C, Dalessandro M, Zingariello P, Mancino P, Petrarca C et al (2006) Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 36(2): 144-150. PubMed PMID: 16682509.
4. Bertoletti A, Naoumov NV (2003) Translation of immunological knowledge into better treatments of chronic hepatitis B. J Hepatol 39(1): 115-124. doi: 10.1016/s0168-8278(03)00126-0. PubMed PMID: 12821053.
5. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y (2015) T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis 6: 1694. doi: 10.1038/cddis.2015.42. PubMed PMID: 25789969; PubMed Central PMCID: PMCPMC4385920.
6. Sharpe AH, Freeman GJ (2002) The B7-CD28 superfamily. Nat Rev Immunol 2(2): 116-126. doi: 10.1038/nri727. PubMed PMID: 11910893.
7. Zhu X, Soluble JL (2017) PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget 8(57): 97671-97682. doi: 10.18632/oncotarget.18311.
8. Bi C, Huang D, Jiang J, Jiang Y, Wang H, Bian C et al (2018) Changes of serum sPD-1 levels in HBeAg-positive chronic hepatitis B patients with entecavir treatment and correlation with curative effect. Turk J Med Sci 48(2): 286-292. doi: 10.3906/sag-1708-121. PubMed PMID: 29714442.
9. Li N, Zhou Z, Li F, Sang J, Han Q, Lv Y et al (2017) Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 8(28): 46020-46033. doi: 10.18632/oncotarget.17546. PubMed PMID: 28545019; PubMed Central PMCID: PMCPMC5542245.
10. Zhou L, Li X, Huang X, Chen L, Gu L, Huang Y (2019) Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B. J Viral Hepat 26(7): 795-802. Epub 2018/12/24. doi: 10.1111/jvh.13055. PubMed PMID: 30578715; PubMed Central PMCID: PMCPMC6849537.
11. Wang D, Zhou D, Du Q, Liang Q, Wang Q, Fang L et al (2013) Aberrant production of soluble inducible T-cell co-stimulator (sICOS) and soluble programmed cell death protein 1 (sPD-1) in patients with chronic hepatitis C. Mol Med Rep 7(4): 1197-202. Epub 2013/02/22. doi: 10.3892/mmr.2013.1326. PubMed PMID: 23426717.
12. Yu X, Pan Y, Fei Q, Lin X, Chen Z, Huang H (2021) Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis. Immun Inflamm Dis 9(1): 310-318. doi: 10.1002/iid3.394. PubMed PMID: 33417300; PubMed Central PMCID: PMCPMC7860599.
13. Bakhshiani Z, Fouladi S, Mohammadzadeh S, Eskandari N (2021) Correlation of sPD1 with Procalcitonin and C-Reactive protein levels in patients with sepsis. Cell J 23(1): 14-20. doi: 10.22074/cellj.2021.6941. PubMed PMID: 33650816; PubMed Central PMCID: PMCPMC7944127.
14. Hadley T, Gillespie S, Espinoza H, Prince J, Gronbaek H, Chandrakasan S et al (2020) Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. Autoimmunity 53(5): 253-260. Epub 2020/05/07. doi: 10.1080/08916934.2020.1755964. PubMed PMID: 32370568.
15. Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L et al (2018) Inflammatory cytokines IL-17 and TNF-alpha up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 184: 7-14. doi: 10.1016/j.imlet.2017.02.006. PubMed PMID: 28223102; PubMed Central PMCID: PMCPMC5362328.
16. Dong Y, Sun Q, Zhang X (2017) PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget 8(2): 2171-86. doi: 10.18632/ oncotarget.13895. PubMed PMID: 27974689; PubMed Central PMCID: PMCPMC5356790.
17. Chang B, Huang T, Wei H, Shen L, Zhu D, He W et al (2019) The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother 68(3): 353-363. doi: 10.1007/s00262-018-2271-4. PubMed PMID: 30506460; PubMed Central PMCID: PMCPMC6426820.
18. Wang G, Wang S, Zhang M, Li Y, Liu Q, Sun N et al (2020) EV PD-L1 is correlated with clinical features and contributes to T cell suppression in pediatric thyroid cancer. J Clin Endocrinol Metab 105(8). doi: 10.1210/clinem/dgaa309. PubMed PMID: 32459310.
19. Zhu X, Lang J (2017) Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. Oncotarget 8(57): 97671-97682. doi: 10.18632/ oncotarget.18311. PubMed PMID: 29228642; PubMed Central PMCID: PMCPMC5722594.
20. Chen Y, Wang Q, Shi B, Xu P, Hu Z, Bai L et al (2011) Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. Cytokine 56(2): 231-238. Epub 2011/07/08. doi: 10.1016/j.cyto. 2011.06.004. PubMed PMID: 21733718.
21. Badoual C, Hans S, Merillon N, Van Ryswick C, Ravel P, Benhamouda N et al (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73(1): 128-138. doi: 10.1158/0008-5472.CAN-12-2606. PubMed PMID: 23135914.
22. Yamagiwa S, Ishikawa T, Waguri N, Sugitani S, Kamimura K, Tsuchiya A et al (2017) Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C. Int J Med Sci 14(5): 403-411. doi: 10.7150/ijms.18784. PubMed PMID: 28539815; PubMed Central PMCID: PMCPMC5441031.
23. Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X et al (2020) Profiles of serum soluble programmed death-1 and programmed death-ligand 1 levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther 51(11): 1180-1187. Epub 2020/05/05. doi: 10.1111/apt.15732. PubMed PMID: 32363582.
Article Sidebar
Published
Dec 13, 2021
Section
Articles
How to Cite
HoanN. X., HuyenP. T. M., HoanP. Q., HinhQ. X., & DuongV. P. (2021). Correlation between plasma levels of sPD-1 and sPD-L1 with hepatic inflammation in chronic HBV infected patients. Tạp Chí Y Dược lâm sàng 108, 16(TA). https://doi.org/10.52389/ydls.v16iTA.1117